
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) Stock Competitors & Peer Comparison
See ARQT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ARQT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ARQT | $28.26 | +2.65% | 3.6B | 134.57 | $0.21 | N/A |
| VRTX | $538.60 | -0.74% | 136.6B | 28.30 | $19.03 | N/A |
| REGN | $955.47 | +0.45% | 98.8B | 20.94 | $45.63 | +0.38% |
| MRNA | $223.37 | -3.45% | 90.4B | -27.41 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $960.04 | -2.17% | 60B | 34.62 | $27.73 | N/A |
| ONC | $416.54 | +0.14% | 44.5B | 73.33 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $172.29 | -2.30% | 37.3B | -19.53 | -$8.82 | N/A |
| RVMDW | $7.68 | -5.83% | 35.9B | -0.87 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ARQT vs VRTX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, VRTX has a market cap of 136.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while VRTX trades at $538.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas VRTX's P/E ratio is 28.30. In terms of profitability, ARQT's ROE is +0.14%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, ARQT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ARQT vs REGN Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, REGN has a market cap of 98.8B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while REGN trades at $955.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas REGN's P/E ratio is 20.94. In terms of profitability, ARQT's ROE is +0.14%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ARQT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
ARQT vs MRNA Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, MRNA has a market cap of 90.4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while MRNA trades at $223.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas MRNA's P/E ratio is -27.41. In terms of profitability, ARQT's ROE is +0.14%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, ARQT is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
ARQT vs VRNA Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ARQT's ROE is +0.14%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, ARQT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ARQT vs ARGX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ARGX has a market cap of 60B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ARGX trades at $960.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ARGX's P/E ratio is 34.62. In terms of profitability, ARQT's ROE is +0.14%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, ARQT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
ARQT vs ONC Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ONC has a market cap of 44.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ONC trades at $416.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ONC's P/E ratio is 73.33. In terms of profitability, ARQT's ROE is +0.14%, compared to ONC's ROE of +0.18%. Regarding short-term risk, ARQT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
ARQT vs SGEN Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ARQT's ROE is +0.14%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ARQT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ARQT vs RVMD Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, RVMD has a market cap of 37.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while RVMD trades at $172.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas RVMD's P/E ratio is -19.53. In terms of profitability, ARQT's ROE is +0.14%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, ARQT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ARQT vs RVMDW Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, RVMDW has a market cap of 35.9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while RVMDW trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas RVMDW's P/E ratio is -0.87. In terms of profitability, ARQT's ROE is +0.14%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, ARQT is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RVMDW's competition here
Genmab A/S (NASDAQ: GMAB)
ARQT vs GMAB Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, GMAB has a market cap of 31.7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while GMAB trades at $51.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas GMAB's P/E ratio is 38.71. In terms of profitability, ARQT's ROE is +0.14%, compared to GMAB's ROE of +0.12%. Regarding short-term risk, ARQT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ARQT vs ROIV Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ROIV has a market cap of 28.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ROIV trades at $39.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ROIV's P/E ratio is -37.61. In terms of profitability, ARQT's ROE is +0.14%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, ARQT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
ARQT vs INSM Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, INSM has a market cap of 26.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while INSM trades at $121.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas INSM's P/E ratio is -42.96. In terms of profitability, ARQT's ROE is +0.14%, compared to INSM's ROE of -0.83%. Regarding short-term risk, ARQT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ARQT vs UTHR Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while UTHR trades at $591.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas UTHR's P/E ratio is 21.15. In terms of profitability, ARQT's ROE is +0.14%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ARQT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
ARQT vs INCY Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, INCY has a market cap of 24.7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while INCY trades at $120.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas INCY's P/E ratio is 16.26. In terms of profitability, ARQT's ROE is +0.14%, compared to INCY's ROE of +0.07%. Regarding short-term risk, ARQT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check INCY's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ARQT vs ALNY Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ALNY has a market cap of 22.1B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ALNY trades at $165.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ALNY's P/E ratio is 8.34. In terms of profitability, ARQT's ROE is +0.14%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, ARQT is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
ARQT vs BNTX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, BNTX has a market cap of 21.2B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while BNTX trades at $85.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas BNTX's P/E ratio is -11.10. In terms of profitability, ARQT's ROE is +0.14%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, ARQT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BNTX's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ARQT vs BGNE Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ARQT's ROE is +0.14%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, ARQT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ARQT vs DNA-WT Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ARQT's ROE is +0.14%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ARQT is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ARQT vs ASND Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ASND has a market cap of 18.1B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ASND trades at $275.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ASND's P/E ratio is -113.80. In terms of profitability, ARQT's ROE is +0.14%, compared to ASND's ROE of +1.08%. Regarding short-term risk, ARQT is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ARQT vs EXEL Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, EXEL has a market cap of 17.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while EXEL trades at $69.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas EXEL's P/E ratio is 19.71. In terms of profitability, ARQT's ROE is +0.14%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, ARQT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ARQT vs NBIX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, NBIX has a market cap of 16.9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while NBIX trades at $167.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas NBIX's P/E ratio is 24.19. In terms of profitability, ARQT's ROE is +0.14%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, ARQT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ARQT vs JAZZ Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, JAZZ has a market cap of 15.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while JAZZ trades at $241.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas JAZZ's P/E ratio is 9.01. In terms of profitability, ARQT's ROE is +0.14%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, ARQT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ARQT vs BBIO Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, BBIO has a market cap of 15.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while BBIO trades at $78.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas BBIO's P/E ratio is -25.76. In terms of profitability, ARQT's ROE is +0.14%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, ARQT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ARQT vs KRTX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ARQT's ROE is +0.14%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ARQT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ARQT vs TECH Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while TECH trades at $72.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas TECH's P/E ratio is 37.53. In terms of profitability, ARQT's ROE is +0.14%, compared to TECH's ROE of +0.08%. Regarding short-term risk, ARQT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check TECH's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ARQT vs HALO Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, HALO has a market cap of 11.4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while HALO trades at $100.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas HALO's P/E ratio is 18.71. In terms of profitability, ARQT's ROE is +0.14%, compared to HALO's ROE of +5.44%. Regarding short-term risk, ARQT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check HALO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ARQT vs SMMT Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, SMMT has a market cap of 11.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while SMMT trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas SMMT's P/E ratio is -12.63. In terms of profitability, ARQT's ROE is +0.14%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, ARQT is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check SMMT's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ARQT vs RNAM Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ARQT's ROE is +0.14%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, ARQT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ARQT vs BMRN Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while BMRN trades at $57.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas BMRN's P/E ratio is 27.51. In terms of profitability, ARQT's ROE is +0.14%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, ARQT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BMRN's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ARQT vs KYMR Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, KYMR has a market cap of 10.9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while KYMR trades at $127.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas KYMR's P/E ratio is -35.24. In terms of profitability, ARQT's ROE is +0.14%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ARQT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check KYMR's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ARQT vs PCVX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while PCVX trades at $63.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas PCVX's P/E ratio is -8.31. In terms of profitability, ARQT's ROE is +0.14%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, ARQT is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check PCVX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ARQT vs MDGL Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while MDGL trades at $427.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas MDGL's P/E ratio is -33.39. In terms of profitability, ARQT's ROE is +0.14%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, ARQT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MDGL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ARQT vs SYRE Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, SYRE has a market cap of 9.9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while SYRE trades at $104.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas SYRE's P/E ratio is -53.33. In terms of profitability, ARQT's ROE is +0.14%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, ARQT is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ARQT vs TGTX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, TGTX has a market cap of 9.8B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while TGTX trades at $64.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas TGTX's P/E ratio is 23.37. In terms of profitability, ARQT's ROE is +0.14%, compared to TGTX's ROE of +0.18%. Regarding short-term risk, ARQT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check TGTX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ARQT vs RXDX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ARQT's ROE is +0.14%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ARQT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RXDX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ARQT vs PRAX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, PRAX has a market cap of 9.2B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while PRAX trades at $328.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas PRAX's P/E ratio is -25.38. In terms of profitability, ARQT's ROE is +0.14%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, ARQT is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check PRAX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ARQT vs NUVL Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ARQT's ROE is +0.14%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ARQT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check NUVL's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ARQT vs KRYS Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, KRYS has a market cap of 9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while KRYS trades at $305.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas KRYS's P/E ratio is 38.25. In terms of profitability, ARQT's ROE is +0.14%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, ARQT is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check KRYS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ARQT vs CRNX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ARQT's ROE is +0.14%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ARQT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ARQT vs IMGN Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ARQT's ROE is +0.14%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ARQT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ARQT vs PTGX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while PTGX trades at $130.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas PTGX's P/E ratio is 127.14. In terms of profitability, ARQT's ROE is +0.14%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, ARQT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ARQT vs APGE Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas APGE's P/E ratio is -31.19. In terms of profitability, ARQT's ROE is +0.14%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ARQT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ARQT vs BPMC Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ARQT's ROE is +0.14%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ARQT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ARQT vs CERE Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas CERE's P/E ratio is -16.47. In terms of profitability, ARQT's ROE is +0.14%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ARQT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CERE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ARQT vs RYTM Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, RYTM has a market cap of 8B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while RYTM trades at $115.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas RYTM's P/E ratio is -36.98. In terms of profitability, ARQT's ROE is +0.14%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, ARQT is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check RYTM's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ARQT vs CYTK Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while CYTK trades at $56.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas CYTK's P/E ratio is -7.77. In terms of profitability, ARQT's ROE is +0.14%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, ARQT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CYTK's competition here
Abivax S.A. (NASDAQ: ABVX)
ARQT vs ABVX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ABVX trades at $87.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ABVX's P/E ratio is -14.35. In terms of profitability, ARQT's ROE is +0.14%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, ARQT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ABVX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ARQT vs AXSM Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, AXSM has a market cap of 7.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while AXSM trades at $141.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas AXSM's P/E ratio is -36.99. In terms of profitability, ARQT's ROE is +0.14%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, ARQT is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check AXSM's competition here
Metsera, Inc. (NASDAQ: MTSR)
ARQT vs MTSR Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ARQT's ROE is +0.14%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, ARQT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MTSR's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
ARQT vs TWST Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, TWST has a market cap of 7.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while TWST trades at $111.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas TWST's P/E ratio is -50.27. In terms of profitability, ARQT's ROE is +0.14%, compared to TWST's ROE of -0.23%. Regarding short-term risk, ARQT is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check TWST's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ARQT vs ORKA Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ORKA has a market cap of 7.1B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ORKA trades at $105.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ORKA's P/E ratio is -54.30. In terms of profitability, ARQT's ROE is +0.14%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, ARQT is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check ORKA's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ARQT vs IMVT Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, IMVT has a market cap of 7.1B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while IMVT trades at $34.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas IMVT's P/E ratio is -12.12. In terms of profitability, ARQT's ROE is +0.14%, compared to IMVT's ROE of -0.63%. Regarding short-term risk, ARQT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ARQT vs TXG Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, TXG has a market cap of 7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while TXG trades at $58.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas TXG's P/E ratio is -98.63. In terms of profitability, ARQT's ROE is +0.14%, compared to TXG's ROE of -0.08%. Regarding short-term risk, ARQT is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check TXG's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
ARQT vs KOD Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, KOD has a market cap of 7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while KOD trades at $111.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas KOD's P/E ratio is -26.66. In terms of profitability, ARQT's ROE is +0.14%, compared to KOD's ROE of -2.88%. Regarding short-term risk, ARQT is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check KOD's competition here
Merus N.V. (NASDAQ: MRUS)
ARQT vs MRUS Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ARQT's ROE is +0.14%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, ARQT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MRUS's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ARQT vs ARWR Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ARWR has a market cap of 6.7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ARWR trades at $47.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ARWR's P/E ratio is -21.24. In terms of profitability, ARQT's ROE is +0.14%, compared to ARWR's ROE of -0.75%. Regarding short-term risk, ARQT is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check ARWR's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ARQT vs ACLX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ARQT's ROE is +0.14%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, ARQT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ACLX's competition here
CG Oncology Inc. (NASDAQ: CGON)
ARQT vs CGON Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while CGON trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas CGON's P/E ratio is -27.66. In terms of profitability, ARQT's ROE is +0.14%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ARQT is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check CGON's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ARQT vs BLTE Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while BLTE trades at $164.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas BLTE's P/E ratio is -87.89. In terms of profitability, ARQT's ROE is +0.14%, compared to BLTE's ROE of -0.17%. Regarding short-term risk, ARQT is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check BLTE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ARQT vs CAI Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, CAI has a market cap of 6.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while CAI trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas CAI's P/E ratio is 64.74. In terms of profitability, ARQT's ROE is +0.14%, compared to CAI's ROE of +0.16%. Regarding short-term risk, ARQT is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check CAI's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ARQT vs RETA Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas RETA's P/E ratio is -66.29. In terms of profitability, ARQT's ROE is +0.14%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ARQT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RETA's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ARQT vs IBRX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, IBRX has a market cap of 6.4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while IBRX trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas IBRX's P/E ratio is -6.21. In terms of profitability, ARQT's ROE is +0.14%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, ARQT is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check IBRX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ARQT vs CNTA Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ARQT's ROE is +0.14%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ARQT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ARQT vs LGND Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, LGND has a market cap of 6.2B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while LGND trades at $308.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas LGND's P/E ratio is 33.90. In terms of profitability, ARQT's ROE is +0.14%, compared to LGND's ROE of +0.05%. Regarding short-term risk, ARQT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check LGND's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ARQT vs MIRM Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while MIRM trades at $93.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas MIRM's P/E ratio is -6.46. In terms of profitability, ARQT's ROE is +0.14%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, ARQT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MIRM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ARQT vs TERN Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas TERN's P/E ratio is -51.41. In terms of profitability, ARQT's ROE is +0.14%, compared to TERN's ROE of -0.14%. Regarding short-term risk, ARQT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check TERN's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ARQT vs CDTX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ARQT's ROE is +0.14%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, ARQT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ARQT vs ABCM Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ARQT's ROE is +0.14%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ARQT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ARQT vs ISEE Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ARQT's ROE is +0.14%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ARQT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
ARQT vs ERAS Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ERAS trades at $15.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ERAS's P/E ratio is -16.84. In terms of profitability, ARQT's ROE is +0.14%, compared to ERAS's ROE of -0.62%. Regarding short-term risk, ARQT is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check ERAS's competition here
Veradermics, Incorporated (NYSE: MANE)
ARQT vs MANE Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, MANE has a market cap of 5.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while MANE trades at $129.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas MANE's P/E ratio is -41.27. In terms of profitability, ARQT's ROE is +0.14%, compared to MANE's ROE of -0.20%. Regarding short-term risk, ARQT is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check MANE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ARQT vs PTCT Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while PTCT trades at $63.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas PTCT's P/E ratio is -45.35. In terms of profitability, ARQT's ROE is +0.14%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, ARQT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ARQT vs SRRK Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while SRRK trades at $43.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas SRRK's P/E ratio is -12.52. In terms of profitability, ARQT's ROE is +0.14%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, ARQT is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check SRRK's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ARQT vs APLS Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas APLS's P/E ratio is 38.35. In terms of profitability, ARQT's ROE is +0.14%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ARQT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check APLS's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ARQT vs DNTH Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, DNTH has a market cap of 5.2B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while DNTH trades at $91.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas DNTH's P/E ratio is -22.12. In terms of profitability, ARQT's ROE is +0.14%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ARQT is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ARQT vs COGT Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, COGT has a market cap of 5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while COGT trades at $28.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas COGT's P/E ratio is -13.54. In terms of profitability, ARQT's ROE is +0.14%, compared to COGT's ROE of -0.71%. Regarding short-term risk, ARQT is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check COGT's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ARQT vs EWTX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while EWTX trades at $45.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas EWTX's P/E ratio is -24.83. In terms of profitability, ARQT's ROE is +0.14%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, ARQT is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check EWTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ARQT vs TVTX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, TVTX has a market cap of 4.9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while TVTX trades at $50.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas TVTX's P/E ratio is -112.56. In terms of profitability, ARQT's ROE is +0.14%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, ARQT is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check TVTX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ARQT vs IONS Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, IONS has a market cap of 4.8B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while IONS trades at $29.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas IONS's P/E ratio is -8.89. In terms of profitability, ARQT's ROE is +0.14%, compared to IONS's ROE of -1.20%. Regarding short-term risk, ARQT is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check IONS's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ARQT vs ADPT Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ADPT has a market cap of 4.7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ADPT trades at $29.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ADPT's P/E ratio is -70.83. In terms of profitability, ARQT's ROE is +0.14%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, ARQT is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ARQT vs FOLD Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ARQT's ROE is +0.14%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, ARQT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ARQT vs AKRO Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ARQT's ROE is +0.14%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, ARQT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ARQT vs ALPN Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ARQT's ROE is +0.14%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ARQT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ALPN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ARQT vs DFTX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, DFTX has a market cap of 4.4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while DFTX trades at $32.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas DFTX's P/E ratio is N/A. In terms of profitability, ARQT's ROE is +0.14%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, ARQT is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check DFTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ARQT vs TNGX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while TNGX trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas TNGX's P/E ratio is -30.72. In terms of profitability, ARQT's ROE is +0.14%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, ARQT is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
ARQT vs OPT Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas OPT's P/E ratio is -1.52. In terms of profitability, ARQT's ROE is +0.14%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ARQT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ARQT vs PRTC Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ARQT's ROE is +0.14%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ARQT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ARQT vs MRTX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ARQT's ROE is +0.14%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ARQT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MRTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ARQT vs CRSP Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, CRSP has a market cap of 4.1B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while CRSP trades at $42.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas CRSP's P/E ratio is -8.87. In terms of profitability, ARQT's ROE is +0.14%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, ARQT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CRSP's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ARQT vs RLAY Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while RLAY trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas RLAY's P/E ratio is -11.52. In terms of profitability, ARQT's ROE is +0.14%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, ARQT is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check RLAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ARQT vs XENE Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, XENE has a market cap of 4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while XENE trades at $40.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas XENE's P/E ratio is -8.61. In terms of profitability, ARQT's ROE is +0.14%, compared to XENE's ROE of -0.40%. Regarding short-term risk, ARQT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check XENE's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
ARQT vs TARS Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, TARS has a market cap of 4B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while TARS trades at $80.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas TARS's P/E ratio is -73.65. In terms of profitability, ARQT's ROE is +0.14%, compared to TARS's ROE of -2.46%. Regarding short-term risk, ARQT is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check TARS's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
ARQT vs AMLX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, AMLX has a market cap of 3.9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while AMLX trades at $30.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas AMLX's P/E ratio is -20.19. In terms of profitability, ARQT's ROE is +0.14%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, ARQT is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check AMLX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ARQT vs CPRX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas CPRX's P/E ratio is 17.49. In terms of profitability, ARQT's ROE is +0.14%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ARQT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
ARQT vs ABCL Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ABCL trades at $11.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ABCL's P/E ratio is -21.28. In terms of profitability, ARQT's ROE is +0.14%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, ARQT is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check ABCL's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ARQT vs RYZB Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ARQT's ROE is +0.14%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ARQT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ARQT vs CBAY Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ARQT's ROE is +0.14%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ARQT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ARQT vs VKTX Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while VKTX trades at $29.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas VKTX's P/E ratio is -5.41. In terms of profitability, ARQT's ROE is +0.14%, compared to VKTX's ROE of -1.17%. Regarding short-term risk, ARQT is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check VKTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ARQT vs ELVN Comparison November 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.6B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, ARQT is priced at $28.26 on the NASDAQ, while ELVN trades at $48.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 134.57, whereas ELVN's P/E ratio is -29.22. In terms of profitability, ARQT's ROE is +0.14%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, ARQT is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ELVN's competition here